GlassScriptPhysician profile
Matthew B Albright
NPI 1578778890
$1,338.28
in general payments reported to CMS, 2019-2025
18 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $240 · 2021: $37.95 · 2022: $190 · 2023: $98.10 · 2024: $242 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $343.09 | 2019-2025 | Clareon |
| Allergan, INC. | $155.62 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $155.17 | 2019 | |
| Sight Sciences, INC. | $147.72 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alexion Pharmaceuticals, INC. | $96.85 | 2022-2023 | Soliris, Ultomiris |
| Glaukos Corporation | $94.43 | 2020-2025 | Photrexa Viscous and Photrexa, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.95 | 2019 | |
| Ocular Therapeutix, INC. | $62.26 | 2024 | Dextenza |
| Bausch & Lomb Americas INC. | $37.39 | 2024 | Xipere, Vyzulta |
| Thea Pharma INC. | $33.92 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $22.08 | 2022 | |
| Biotissue Holdings INC. | $22.00 | 2025 | |
| Rxsight INC | $17.55 | 2022 | |
| Boston Scientific Corporation | $17.50 | 2024 | Wavewriter Alpha Prime 16 |
| Catalyst Pharmaceuticals, INC. | $15.93 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $15.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.79 | 2020 | |
| Travere Therapeutics, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Albright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.